New evidence highlights the power of Natera’s latest ultrasensitive molecular residual disease (MRD) technology, Signatera ...
Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with ...
Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for ...
AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the ...
Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of ...
Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will ...
As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering ...
Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in ...
Industry-Leading Pulse Oximetry Platform Now Features First-of-Its-Kind Atrial Fibrillation (AFib) Detection with Previously ...
HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a ...
Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”) (SSE: 688321) today announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed ...
Kexing Biopharm (688136.SH) recently announced that it has received a Notice of Acceptance from China’s National Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results